191 related articles for article (PubMed ID: 22039081)
1. Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival.
Italiano A; Toulmonde M; Cioffi A; Penel N; Isambert N; Bompas E; Duffaud F; Patrikidou A; Lortal B; Le Cesne A; Blay JY; Maki RG; Schwartz GK; Antonescu CR; Singer S; Coindre JM; Bui B
Ann Oncol; 2012 Jun; 23(6):1601-7. PubMed ID: 22039081
[TBL] [Abstract][Full Text] [Related]
2. Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery.
Keung EZ; Hornick JL; Bertagnolli MM; Baldini EH; Raut CP
J Am Coll Surg; 2014 Feb; 218(2):206-17. PubMed ID: 24315890
[TBL] [Abstract][Full Text] [Related]
3. Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma.
Thirasastr P; Lin H; Amini B; Wang WL; Cloutier JM; Nassif EF; Keung EZ; Roland CL; Feig B; Araujo D; Benjamin RS; Conley AP; Livingston JA; Ludwig J; Patel S; Ratan R; Ravi V; Zarzour MA; Zhou X; Somaiah N
Cancer Med; 2023 Feb; 12(4):4282-4293. PubMed ID: 36151848
[TBL] [Abstract][Full Text] [Related]
4. Impact of chemotherapy on survival in surgically resected retroperitoneal sarcoma.
Miura JT; Charlson J; Gamblin TC; Eastwood D; Banerjee A; Johnston FM; Turaga KK
Eur J Surg Oncol; 2015 Oct; 41(10):1386-92. PubMed ID: 26251340
[TBL] [Abstract][Full Text] [Related]
5. Influence of age and subtype in outcome of operable liposarcoma.
Greto D; Saieva C; Loi M; Terziani F; Visani L; Garlatti P; Lo Russo M; Muntoni C; Becherini C; Topulli J; Campanacci D; Beltrami G; Scoccianti G; Muratori F; Bonomo P; Desideri I; Francolini G; Livi L
Radiol Med; 2019 Apr; 124(4):290-300. PubMed ID: 30421387
[TBL] [Abstract][Full Text] [Related]
6. Correlation of histological grade of dedifferentiation with clinical outcome in 55 patients with dedifferentiated liposarcomas.
Dantey K; Schoedel K; Yergiyev O; Bartlett D; Rao UNM
Hum Pathol; 2017 Aug; 66():86-92. PubMed ID: 28300575
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group.
Haas RLM; Bonvalot S; Miceli R; Strauss DC; Swallow CJ; Hohenberger P; van Coevorden F; Rutkowski P; Callegaro D; Hayes AJ; Honoré C; Fairweather M; Gladdy R; Jakob J; Szacht M; Fiore M; Chung PW; van Houdt WJ; Raut CP; Gronchi A
Cancer; 2019 Apr; 125(8):1290-1300. PubMed ID: 30602058
[TBL] [Abstract][Full Text] [Related]
8. Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center.
Nassif EF; Cope B; Traweek R; Witt RG; Erstad DJ; Scally CP; Thirasastr P; Zarzour MA; Ludwig J; Benjamin R; Bishop AJ; Guadagnolo BA; Ingram D; Wani K; Wang WL; Lazar AJ; Torres KE; Hunt KK; Feig BW; Roland CL; Somaiah N; Keung EZ
Int J Cancer; 2022 Jun; 150(12):2012-2024. PubMed ID: 35128664
[TBL] [Abstract][Full Text] [Related]
9. Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group.
Toulmonde M; Bonvalot S; Ray-Coquard I; Stoeckle E; Riou O; Isambert N; Bompas E; Penel N; Delcambre-Lair C; Saada E; Lecesne A; Le Péchoux C; Blay JY; Piperno-Neumann S; Chevreau C; Bay JO; Brouste V; Terrier P; Ranchère-Vince D; Neuville A; Italiano A;
Ann Oncol; 2014 Mar; 25(3):730-734. PubMed ID: 24496921
[TBL] [Abstract][Full Text] [Related]
10. Advanced chondrosarcomas: role of chemotherapy and survival.
Italiano A; Mir O; Cioffi A; Palmerini E; Piperno-Neumann S; Perrin C; Chaigneau L; Penel N; Duffaud F; Kurtz JE; Collard O; Bertucci F; Bompas E; Le Cesne A; Maki RG; Ray Coquard I; Blay JY
Ann Oncol; 2013 Nov; 24(11):2916-22. PubMed ID: 24099780
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety of combination therapy with chemotherapy, programmed death-1 inhibitor and anlotinib in the treatment of advanced dedifferentiated liposarcoma].
Guo X; Zhuang RY; Zhou YH; You CL; Zhang Y; Feng F; Shen ZM; Wang WS; Liu Y; Zhang HX; Tong WQ; Lu RK; Luo R
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2428-2434. PubMed ID: 36000371
[No Abstract] [Full Text] [Related]
12. Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin.
Fabbroni C; Fucà G; Ligorio F; Fumagalli E; Barisella M; Collini P; Morosi C; Gronchi A; Dei Tos AP; Casali PG; Sanfilippo R
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33810165
[TBL] [Abstract][Full Text] [Related]
13. Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms.
Kyriazoglou A; Pagkali A; Kotsantis I; Economopoulou P; Kyrkasiadou M; Moutafi M; Gavrielatou N; Anastasiou M; Boulouta A; Pantazopoulos A; Giannakakou M; Digklia A; Psyrri A
Cancer Treat Rev; 2024 Apr; 125():102716. PubMed ID: 38492514
[TBL] [Abstract][Full Text] [Related]
14. Differences in recurrence and survival of extremity liposarcoma subtypes.
Vos M; Koseła-Paterczyk H; Rutkowski P; van Leenders GJLH; Normantowicz M; Lecyk A; Sleijfer S; Verhoef C; Grünhagen DJ
Eur J Surg Oncol; 2018 Sep; 44(9):1391-1397. PubMed ID: 29673808
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of prognostic factors for liposarcoma].
Zhang Q; Li JM; Liu JL; Wei YZ
Zhonghua Zhong Liu Za Zhi; 2019 Dec; 41(12):943-948. PubMed ID: 31874553
[No Abstract] [Full Text] [Related]
16. Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard.
Livingston JA; Bugano D; Barbo A; Lin H; Madewell JE; Wang WL; Lazar AJ; Tseng WW; Roland CL; Feig BW; Pollock R; Conley AP; Benjamin RS; Patel S; Somaiah N
Sci Rep; 2017 Sep; 7(1):11836. PubMed ID: 28928422
[TBL] [Abstract][Full Text] [Related]
17. Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma.
Gronchi A; Collini P; Miceli R; Valeri B; Renne SL; Dagrada G; Fiore M; Sanfilippo R; Barisella M; Colombo C; Morosi C; Stacchiotti S; Casali PG; Dei Tos AP; Pilotti S
Am J Surg Pathol; 2015 Mar; 39(3):383-93. PubMed ID: 25581729
[TBL] [Abstract][Full Text] [Related]
18. Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation.
Henricks WH; Chu YC; Goldblum JR; Weiss SW
Am J Surg Pathol; 1997 Mar; 21(3):271-81. PubMed ID: 9060596
[TBL] [Abstract][Full Text] [Related]
19. Metastasis in dedifferentiated liposarcoma: Predictors and outcome in 148 patients.
Tirumani SH; Tirumani H; Jagannathan JP; Shinagare AB; Hornick JL; Ramaiya NH; Wagner AJ
Eur J Surg Oncol; 2015 Jul; 41(7):899-904. PubMed ID: 25659772
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
